Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Lead Sponsor:

Queen Mary University of London

Collaborating Sponsors:

AstraZeneca

Conditions:

Estrogen Receptor Positive Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanc...

Detailed Description

This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanc...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Written informed consent prior to admission to this study
  • Women, age ≥18 years
  • Histologically confirmed breast cancer
  • Metastatic or locally recurrent disease; locally recurrent disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible).
  • Patients must have:
  • at least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computed tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements, or
  • lytic or mixed (lytic + sclerotic) bone lesions in the absence of measurable disease as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible
  • Radiological or clinical evidence of recurrence or progression
  • ER-positive disease
  • HER2-negative disease with 0, 1+ or 2+ intensity on IHC and no evidence of amplification on ISH.
  • Formalin fixed, paraffin embedded tumour sample from the primary and/or recurrent cancer must be available for central testing
  • Postmenopausal women.
  • Disease refractory to aromatase inhibitors (AI)
  • Haematologic and biochemical indices within acceptable limits
  • ECOG performance status 0-2
  • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, bilateral oophorectomy, bilateral tubular ligation or is post-menopausal (total cessation of menses for ≥ 1 year
  • Exclusion criteria:
  • Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitic spread. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not compromised as a result of disease.
  • More than one line of prior chemotherapy for metastatic breast cancer
  • Prior chemotherapy, biological therapy, androgens, thalidomide, immunotherapy, other anticancer agents or any investigational agents within 14 days of starting study treatment (not including palliative radiotherapy at focal sites), radiotherapy with a wide field of radiation (greater than or equal to 30% marrow or whole pelvis or spine) within 4 weeks of starting study treatment, or strontium-90 (or other radiopharmaceuticals) within the past 3 months or major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access); with the exception of alopecia, all unresolved toxicities from prior treatment should be no greater than CTCAE grade 1 at the time of starting study treatment
  • Prior treatment with fulvestrant or everolimus
  • Prior treatment with PI3K inhibitors, Akt inhibitors or other mTOR inhibitors.
  • Patients receiving concomitant immunosuppressive agents or chronic systemic corticosteroids (≥10 mg prednisolone or an equivalent dose of other anti-inflammatory corticosteroids) use for ≥28 days at the time of study entry except in cases outlined below: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed. Patients on stable low dose of corticosteroids for at least two weeks before randomisation are allowed
  • Current refractory nausea and vomiting, chronic gastrointestinal disease or inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of the study medication
  • Clinically significant pulmonary dysfunction
  • Significant cardiovascular disease
  • QTc prolongation defined as a QTc interval \>470 msecs or other significant ECG abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia (ventricular rate \<50 beats/min)
  • Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age)
  • Clinically significant abnormalities of glucose metabolism
  • Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 within 2 weeks before the first dose of study treatment
  • Exposure to potent or moderate inhibitors or inducers of CYP2C8 within 1 week before the first dose of study treatment.
  • Application of haemopoietic growth factors (e.g. G-CSF, GM-CSF) within 2 weeks before receiving study drug
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
  • History of hypersensitivity to active or inactive excipients of AZD2014 or everolimus or drugs with a similar chemical structure or class to AZD2014 or everolimus
  • History of hypersensitivity to active or inactive excipients of fulvestrant and/or castor oil.
  • Patients presenting with anaemia symptoms (haemoglobin ≤ 90 g/L).
  • Currently receiving (and are unwilling to discontinue) oestrogen replacement therapy (last dose ≤ 7 days prior to randomisation)
  • Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol.
  • Detained persons or prisoners
  • Pregnant or nursing women (including no breast feeding from two weeks before the first dose of study medication, till 8 weeks after the last dose of study medication).

Exclusion

    Key Trial Info

    Start Date :

    January 16 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 31 2021

    Estimated Enrollment :

    333 Patients enrolled

    Trial Details

    Trial ID

    NCT02216786

    Start Date

    January 16 2014

    End Date

    December 31 2021

    Last Update

    December 2 2024

    Active Locations (79)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 20 (79 locations)

    1

    ICO Paul Papin

    Angers, France

    2

    Institut Sainte Catherine

    Avignon, France

    3

    Antoine Lacassagne Centre De Lutte Contre Le Cancer De Nice

    Nice, France

    4

    Hospital Center Private Saint-Grégoire

    Saint-Grégoire, France